Mild to moderate Alzheimer’s disease


Does one of your loved ones have the onset of Alzheimer's?


Alzheimer's disease is an age-related neurodegenerative disease characterized by a progressive decline in cognitive function and the ability to perform activities of daily living.

Have you noticed a decrease in the memory capacity of someone close to you?

The present clinical study aims to demonstrate that the medication currently used for this research slows cognitive and functional decline and safety in participants with symptoms of Alzheimer's disease.

To participate, you must:

  • Be aged 50 or over
  • Have a diagnosis of mild to moderate Alzheimer's


You will be reimbursed for study-related expenses when you participate in the clinical study and you will be surrounded by a medical team throughout the process.

I want to apply to this clinical study


For more information, contact us at 819 346-2887 (Sherbrooke) or at 1-844-739-3439 (toll free), or fill the online form.

The study process in pictures


Step 1 | Before starting the study, we will take time to fully explain the selection process and the conduct of the study by phone.


Step 2 | After the initial phone interview, if you are still interested in taking part in a study, we schedule a preliminary meeting with you during which you may ask all the questions you wish and take the time you require to read over the consent form. This form explains, in detail, the different stages of each study.


Step 3 | You may make a decision at that time to move forward with or terminate the selection process. However, you are under no obligation to make an immediate decision. Based on briefing content, you may take the time necessary to come to a decision and consult with your personal physician or loved ones.


Step 4 | Depending on the nature of the study, some tests or medical examinations may be required. In the majority of cases, these tests or examinations are conducted on Diex Research premises based on your individual availability.


Step 5 | If you are eligible, you may then begin a clinical study with us.